

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Tuberculosis (TB)	LSR2 protein precursor	<i>In vitro</i> studies suggest that inhibiting <i>Mycobacterium tuberculosis</i> LSR2 could help treat TB. <i>In vitro</i> , LSR2 bound to DNA and protected it from reactive oxygen-induced degradation. In <i>M. smegmatis</i> , a related mycobacterium, <i>lsr2</i> <sup>-/-</sup> bacteria were more susceptible to the reactive oxygen intermediate H <sub>2</sub> O <sub>2</sub> than wild-type controls, whereas mutants overexpressing <i>lsr2</i> had better survival. Next steps could include developing LSR2 inhibitors and testing their therapeutic potential in animal models of TB.	Patent and licensing status unavailable	Colangeli, R. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Feb. 16, 2009; doi:10.1073/pnas.0810126106 <b>Contact:</b> R. Colangeli, University of Medicine and Dentistry of New Jersey, Newark, N.J. e-mail: <a href="mailto:colangro@umdnj.edu">colangro@umdnj.edu</a>
		<b>SciBX 2(8); doi:10.1038/scibx.2009.321</b> <b>Published online Feb. 26, 2009</b>		